Idiopathic Pulmonary Fibrosis clinical trials at UCSD
2 in progress, 0 open to eligible people
Showing trials for
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, not currently recruiting here
Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.
La Jolla, California and other locations
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Sorry, in progress, not accepting new patients
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
San Diego, California and other locations
Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include Gordon Yung, MD.